Increasing Prevalence of Obesity and Diabetes The rising incidence of obesity and diabetes is a primary driver for the GLP-1 Drug Market
In addition, some studies on recently marketed GLP-1 RAs such as dulaglutide (AWARD studies), albiglutide (HARMONY studies), and lixisenatide (GetGoal studies) included cardiovascular parameters as a part of their non-primary endpoints (Table 2)
Studies suggest that using a PEG tube at the right time may extend life by 36 months (Guillemin et al., 2022)
Prfen Sie auf Allergene wie Konservierungsstoffe und die pH-Werte des Lsungsmittels (ideal: 5,06,5 fr Nasenschleimhautvertrglichkeit)
At week 75, observed mean (SD) changes from baseline were 2 (10)/min with semaglutide, 3 (9)/min with liraglutide, and 2 (10)/min with placebo